Policy

Can anybody spare a dime for science? With the usual funding avenues blocked development-stage companies are turning to research charities.

Biotech organisations in the UK have expressed anger at a tripling of the license fees charged by the Human Tissue Authority, the UK's regulator.

The French medicines regulator has approved the use of gene therapy on a limited basis, the first time it has been made available in Europe in this way.

The bad news is the world is warming faster than forecast. The good: the US is now ready to engage and Clean Tech is top of the agenda, writes Nuala Moran.

The economic crisis has cost Europe’s largest biomedical research charity, the Wellcome Trust. With £2 billion wiped off the value of its assets base.

An across-government group overseeing nanotechnologies in the UK has made a number of pledges to ensure the responsible development of the field.

Everyone’s strapped for cash – except pharma. But the latest spending spree is no more of a fix for expiring patents than botox is for ageing skin, writes Nuala Moran.

The UK has set up a £27 million Sustainable Bioenergy Centre to carry out research to underpin and develop the sustainable bioenergy sector.